Sanofi SA - SNY Earnings per share for the last 12 months

Public company logo of Sanofi Aventis (SNY)

This chart of relative EPS YoY TTM changes demonstrates the impact of the success of Sanofi (SNY) flagship immunology drug on margins. Profit growth is based on the low cost of mass-producing medications and a focus on biotechnology for rare pathologies. The -30.60 mark reflects the latest data, confirming that operating leverage effectively offsets the costs of updating the R&D portfolio.

SNY Sanofi SA: Earnings per share for the last twelve months in the range 02/11/2024 - 11/17/2026

SNY (sanofi.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Fundamental company valuation:SNY - Sanofi SA
Signature product of Sanofi

Patent protection for Sanofi (SNY) drugs creates high barriers to entry, which directly impacts the efficiency of profit generation. By analyzing the YoY TTM growth of net income per share, an investor assesses the 12-month EPS growth trend to determine the fair value of the business. This chart reflects the company's ability to monetize innovation despite regulatory pressure in Europe. The positive momentum confirms the resilience of the operating model and justifies the market premium for control.